Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 388Colorectal Neoplasms 307Rectal Neoplasms 225Stomach Neoplasms 206Pancreatic Neoplasms 137Neoplasm Metastasis 121Colonic Neoplasms 93Neoplasms 85Triple Negative Breast Neoplasms 63Esophageal Neoplasms 57Biliary Tract Neoplasms 37Nasopharyngeal Carcinoma 36Adenocarcinoma 31Cholangiocarcinoma 30Carcinoma, Hepatocellular 30Gallbladder Neoplasms 28Carcinoma, Non-Small-Cell Lung 21Bile Duct Neoplasms 21Locally Advanced Rectal Cancer 20Adenocarcinoma Of Esophagus 20Squamous Cell Carcinoma of Head and Neck 19Gastrointestinal Neoplasms 18Brain Neoplasms 18Parkinson Disease 4, Autosomal Dominant Lewy Body 17Liver Neoplasms 17Head and Neck Neoplasms 17Esophageal Squamous Cell Carcinoma 17Ovarian Neoplasms 14Colorectal Cancer Metastatic 14Breast Neoplasms, Male 14

Interventions

donafenib 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Biliary Malignant Tumors × Capecitabine × Clear all
NCT06685289 2025-01-28

Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
70 enrolled
Gastrointestinal

Biliary Malignant Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡